Skye Bioscience Files S-1/A Amendment

TL;DR

<b>Skye Bioscience, Inc. has filed an S-1/A amendment, providing updated information for its securities registration.</b>

AI Summary

Skye Bioscience, Inc. (SKYE) filed a Amended IPO Registration (S-1/A) with the SEC on April 4, 2024. Skye Bioscience, Inc. filed an S-1/A amendment on April 4, 2024. The company was formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc. The filing relates to the Securities Act of 1933. The company's principal business address is in San Diego, CA. The filing includes financial data for the fiscal years ending December 31, 2023, and December 31, 2022.

Why It Matters

For investors and stakeholders tracking Skye Bioscience, Inc., this filing contains several important signals. This amendment likely contains updated financial statements, business descriptions, or risk factors relevant to potential investors. The S-1/A filing indicates the company is seeking to register additional securities or has made material changes to a previous registration statement.

Risk Assessment

Risk Level: medium — Skye Bioscience, Inc. shows moderate risk based on this filing. The company is in the pharmaceutical preparations industry, which is subject to significant regulatory hurdles and market volatility, as indicated by its SIC code and the nature of S-1/A filings.

Analyst Insight

Investors should review the specific details within the S-1/A filing to understand the company's current financial health, business strategy, and the terms of any securities being registered.

Key Numbers

• 2024-04-04 — Filing Date (S-1/A filing date)
• 2023-12-31 — Fiscal Year End (Fiscal year end date)
• 2022-12-31 — Previous Fiscal Year End (Previous fiscal year end date)
• 333-278286 — SEC File Number (SEC file number for this registration)

Key Players & Entities

• Skye Bioscience, Inc. (company) — Filer name
• Emerald Bioscience, Inc. (company) — Former company name
• Nemus Bioscience, Inc. (company) — Former company name
• LOAD GUARD LOGISTICS, INC. (company) — Former company name
• 2024-04-04 (date) — Filing date
• San Diego, CA (location) — Business address
• 1933 Act (regulation) — SEC Act
• 2834 (industry_code) — Standard Industrial Classification

FAQ

Risk Factors

• Regulatory Risks [medium — regulatory]: The pharmaceutical industry is heavily regulated, and changes in regulations can impact product development, approval, and market access.
• Market Volatility [medium — market]: The company operates in a volatile market, subject to competition and shifts in demand for pharmaceutical products.
• Operational Challenges [medium — operational]: The company may face operational challenges in research, development, manufacturing, and distribution of its products.

Key Dates

• 2024-04-04: S-1/A Filing — Amendment to securities registration statement
• 2019-03-25: Name Change — Formerly Emerald Bioscience, Inc.
• 2014-10-30: Name Change — Formerly Nemus Bioscience, Inc.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC, typically used to update or correct information previously filed. (Indicates the company is providing updated or corrected information regarding its securities offering or registration.)

Filing Documents

• skye-20240404.htm (S-1/A) — 1149KB
• 0001628280-24-014904.txt (&nbsp;) — 9379KB
• skye-20240404.xsd (EX-101.SCH) — 90KB
• skye-20240404_cal.xml (EX-101.CAL) — 103KB
• skye-20240404_def.xml (EX-101.DEF) — 540KB
• skye-20240404_lab.xml (EX-101.LAB) — 869KB
• skye-20240404_pre.xml (EX-101.PRE) — 702KB
• skye-20240404_htm.xml (XML) — 1286KB

From the Filing

skye-20240404 As filed with the Securities and Exchange Commission on April 4, 2024 Registration No. 333-278286 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 SKYE BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 2834 45-0692882 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 11250 El Camino Real, Suite 100 San Diego , CA 92130 (858) 410-0266 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Punit Dhillon Chief Executive Officer Skye Bioscience, Inc. 11250 El Camino Real, Suite 100 San Diego, CA 92130 (858) 410-0266 (Name, address, including zip code, and telephone number, including area code, of agent for service) With copies to: Steven G. Rowles Scott Lesmes John Hensley Morrison & Foerster, LLP 12531 High Bluff Drive, #100 San Diego, CA 92130 Tel: (858) 720-5100 Approximate date of commencement of proposed sale to the public: From time to time after the effective date. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer o Accelerated filer o Non-accelerated filer Smaller reporting company Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. o The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the SEC, acting pursuant to said Section 8(a), may determine. EXPLANATORY NOTE Skye Bioscience, Inc. (the "Company") is filing this Amendment No. 1 on Form S-1/A (this "Amendment") to its Form S-1 which was originally filed with the Securities and Exchange Commission on March 27, 2024 (the "Original Filing"). The purpose of the Amendment is to correct a scrivener's error in the Marcum LLP, Report of Independent Registered Public Accounting Firm ("Auditor's Report"). The scrivener's error in the Auditor's Report concerns the date of the original Auditor's Report, which referenced March 27, 2024 instead of March 21, 2024. No other changes were made to the Auditor's Report. Other than the changes to the Auditor's Report, the prospectus, constituting Part I of the Registration Statement, is unchanged. This Amendment does not reflect events occurring after the filing of the Original Filing or modify or update any amounts or disclosures within the financial statements and should be read in conjunction with the Original Filing made with the Securities and Exchange Commission. 2 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Reports of Independent Registered Public Accounting Firm (PCAOB ID 688 ) F- 2 Consolidated Balance Sheets as of December 31, 2023 and 2022 F- 3 Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 F- 4 Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 F- 5 Consolidated Statements of Stockholders' Deficit for the years ended December 31, 2023 and 2022 F- 7 Notes to the Co

View Full Filing

View this S-1/A filing on SEC EDGAR